All Posts
  • Interviews
1 min read

Bag of Tr1Xs: Off-the-Shelf Type 1 Treg Shows Phase I Promise for GvHD

On this page

Share

In a clinical first, Tr1X Bio showed immune reconstitution and engraftment for allogeneic Tr1 cell therapy, establishing clinical safety and efficacy

Related Articles

Explore posts connected to this topic

View Resources

Tr1X, Inc. to highlight Miltenyi Biotec CDMO capabilities for scalable allogeneic cell therapy manufacturing at the 11th Annual CAR-TCR Summit

San Diego, CA, and Bergisch Gladbach, Germany – September 15, 2026 – Tr1X, Inc. and Miltenyi Biotec today announced that...

  • Press Releases

CIRM approves more than $60 million to support clinical and preclinical development awards

South San Francisco, CA, June 25, 2026 – The California

  • Press Releases

Tr1X to Present New Clinical and Preclinical Data on Engineered Tr1 Treg Cell Therapies at ASGCT 2026

SAN DIEGO–(BUSINESS WIRE)–Tr1X, Inc., a clinical-stage autoimmune and inflammatory disease

  • Press Releases

San Diego, CA, and Bergisch Gladbach, Germany – September 15,

  • Press Releases

South San Francisco, CA, June 25, 2026 – The California

  • Press Releases

SAN DIEGO–(BUSINESS WIRE)–Tr1X, Inc., a clinical-stage autoimmune and inflammatory disease

  • Press Releases